- Trial phase
- Phase 2b
- Time to market
- At least 3-5 years, Phase 2b data expected Q4 2027, followed by potential Phase 3 trials and regulatory filing
- Why 4/10
- The next hard drug-specific catalyst for MAR001/005 is Phase 2b topline data expected in Q4 2027, more than 12 months from now. Per the rubric, a mid-stage drug whose next catalyst is >12 months out scores 3-5. The score of 4 reflects that while MAR001/005 is the lead asset of the combined entity, the near-term binary is corporate (November 9 stockholder vote) rather than clinical, and the extreme dilution of legacy shareholders means the stock is heavily discounted already.
The November 9 stockholder vote is the immediate binary catalyst, failure to approve Series C conversion and reverse split could trigger cash settlement obligations and Nasdaq delisting risk. For MAR001/005 specifically, Phase 2b topline data is not expected until Q4 2027, over a year away. The extreme dilution (~2.39% legacy ownership) means LSTA stock is now effectively a proxy for Marea Therapeutics' pipeline, but with corporate governance overhangs that need resolving first.
Price Chart
Executive Summary
MAR001/005 is a Phase 2b cardioendocrine drug for severe hypertriglyceridemia, developed by the combined entity that emerged from Lisata Therapeutics' (LSTA) September 2026 reverse-merger acquisition of Marea Therapeutics. The transaction transformed LSTA from a clinical-stage oncology company into a cardioendocrine-focused biotech, raising $225 million in a concurrent PIPE from top-tier life science investors. However, legacy LSTA shareholders were diluted to just ~2.39% of the pro-forma entity. The stock trades near $1.00 (52-week low), with a critical stockholder vote on November 9, 2026, to approve Series C Preferred conversion and a reverse stock split needed for Nasdaq listing compliance. The Phase 2b topline readout for MAR001/005 is not expected until Q4 2027.
How It Works
MAR001/005 is a cardioendocrine therapy being developed for severe hypertriglyceridemia, a condition where patients have dangerously high levels of triglycerides (a type of fat) in their blood, raising the risk of pancreatitis and cardiovascular disease. The drug targets metabolic pathways that control triglyceride production and clearance, though its exact molecular mechanism is not fully detailed in available sources. It is intended to reduce triglyceride levels in patients who have not responded adequately to existing treatments.
Trial Status
MAR001/005 is in Phase 2b clinical development for severe hypertriglyceridemia. The drug was originally developed by Marea Therapeutics, which Lisata acquired via reverse merger in September 2026. Topline data from the Phase 2b study is expected in Q4 2027.
The Two-Sided Case
Upcoming Catalysts
- November 9, 2026: Special stockholder meeting to approve Series C Preferred conversion and reverse stock split for Nasdaq compliance
- Q4 2027: Phase 2b topline data readout for MAR001/005 in severe hypertriglyceridemia
Source Filing
The SecBot filing or press-release report that triggered this drug report:
LISATA THERAPEUTICS, INC. DEF 14A LSTA ·Originating report